ANNA-KARINA MARCO: Open Payments
NPI 1992316566 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,061 in 17 payments from 10 companies in 2025. Trend: 2023 $1,325 · 2024 $1,829 · 2025 $2,061
Food & beverage: $2,061
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 4 | $490 |
| AstraZeneca Pharmaceuticals LP | 3 | $388 |
| Amgen Inc. | 2 | $268 |
| ABBVIE INC. | 2 | $225 |
| Stryker Corporation | 1 | $130 |
| GlaxoSmithKline, LLC. | 1 | $122 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $122 |
| Abbott Laboratories | 1 | $116 |
| Lilly USA, LLC | 1 | $105 |
| Averitas Pharma Inc. | 1 | $94 |
Products named: REPATHA, Ozempic, Wegovy, VRAYLAR, FARXIGA, FLOWTRIEVER CATHETER, S, TEZSPIRE, SHINGRIX.
Industry payments across AZ — which companies pay providers there.
